133
Participants
Start Date
July 31, 2012
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
PF-05335810 Dose A
Single SC Injection
PF-05335810 Dose B
Single Subcutaneous Injection(s)
Placebo
Single Subcutaneous Injection(s)
PF-05335810 Dose B
Single Intravenous Infusion
Placebo
Single Intravenous Infusion
PF-04950615 Dose A
Single Subcutaneous Injection(s)
PF-04950615 Dose A
Single Intravenous Infusion
PF-05335810 Dose C
Single Subcutaneous Injection(s)
Placebo
Single Subcutaneous Injection(s)
PF-05335810 Dose C
Single Intravenous Infusion
Placebo
Single Intravenous Infusion
PF-04950615
Single Subcutaneous Injection(s)
PF-05335810 Dose D
Single Subcutaneous Injection(s)
Placebo
Single Subcutaneous Injection(s)
PF-05335810 Dose E
Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.
PF-05335810 Dose D
Single Intravenous Infusion
Placebo
Single Intravenous Infusion
Pfizer Investigational Site, South Miami
Pfizer Investigational Site, Miami
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Kalamazoo
Pfizer Investigational Site, Overland Park
Pfizer Investigational Site, San Antonio
Pfizer Investigational Site, New Haven
Lead Sponsor
Pfizer
INDUSTRY